VERTEX PHARMS INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VERTEX PHARMS INC, and when can generic versions of VERTEX PHARMS INC drugs launch?
VERTEX PHARMS INC has six approved drugs.
There are forty-seven US patents protecting VERTEX PHARMS INC drugs.
There are six hundred and sixty-one patent family members on VERTEX PHARMS INC drugs in forty-seven countries and sixty-eight supplementary protection certificates in nineteen countries.
Summary for VERTEX PHARMS INC
International Patents: | 661 |
US Patents: | 47 |
Tradenames: | 4 |
Ingredients: | 4 |
NDAs: | 6 |
Drugs and US Patents for VERTEX PHARMS INC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | GRANULES;ORAL | 217660-002 | Apr 26, 2023 | RX | Yes | Yes | 10,646,481 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | TABLET;ORAL | 206038-001 | Jul 2, 2015 | RX | Yes | Yes | 8,741,933 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-002 | Mar 17, 2015 | RX | Yes | Yes | 9,670,163 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VERTEX PHARMS INC Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Chile | 2016002600 | ⤷ Try a Trial |
Portugal | 2502911 | ⤷ Try a Trial |
Denmark | 3219705 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for VERTEX PHARMS INC Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2404919 | C02404919/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPANCARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOESAEURE (LUMACAFTOR); REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65981 02.09.2016 |
3170818 | 35/2020 | Austria | ⤷ Try a Trial | PRODUCT NAME: EINE KOMBINATION VON (A) 3-(6-(1-(2,2-DIFLUORBENZO(D)(1,3)DIOXOL-5-YL)CYCLOPROPANCARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOESAEURE UND (B) N-(5-HYDROXY-2,4-DITERT-BUTYLPHENYL)-4-OXO-1H-CHINOLIN-3-CARBOXAMID ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1059 20151124 |
3170818 | C202030042 | Spain | ⤷ Try a Trial | PRODUCT NAME: UNA COMBINACION DE A) LUMACAFTOR Y B) IVACAFTOR; NATIONAL AUTHORISATION NUMBER: EU/1/15/1059; DATE OF AUTHORISATION: 20151119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1059; DATE OF FIRST AUTHORISATION IN EEA: 20151119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.